Tyra Biosciences Reports Q1 Results, Extends Cash Runway to H2 2028 with $147.9M ATM Proceeds

summarizeSummary

Tyra Biosciences filed its Q1 2026 report, detailing an extended cash runway into the second half of 2028, supported by $147.9 million in net proceeds from its at-the-market offering program.

check_boxKey Events

• Cash Runway Extended

  The company's cash, cash equivalents, and marketable securities of $383.5 million as of March 31, 2026, are projected to fund operations into the second half of 2028, extending the previous guidance of 'at least 2027'.

• ATM Offering Nearly Fully Utilized

  Tyra Biosciences raised $147.9 million in net proceeds during Q1 2026 by selling 4,690,532 shares through its $150 million at-the-market (ATM) offering program, which was established in May 2025.

• Increased Operating Expenses

  Research and development expenses increased to $33.5 million in Q1 2026 from $25.0 million in Q1 2025, and general and administrative expenses rose to $8.5 million from $6.9 million, reflecting ongoing pipeline advancement.

• Net Loss Widened

  The company reported a net loss of $39.3 million for Q1 2026, compared to a net loss of $28.1 million for the same period in 2025.

auto_awesomeAnalysis

This quarterly report provides the detailed financial results for Q1 2026, confirming the company's cash, cash equivalents, and marketable securities of $383.5 million are sufficient to fund operations into the second half of 2028. This extends the previously disclosed runway of 'through at least 2027' from the last 10-K. The improved liquidity is largely due to the utilization of its at-the-market (ATM) offering program, which generated $147.9 million in net proceeds during the quarter, nearly exhausting the $150 million program. While the company reported an increased net loss of $39.3 million and higher operating expenses, these reflect continued investment in its clinical pipeline. Several executives also adopted routine 10b5-1 trading plans during the quarter, which are pre-planned arrangements and not indicative of immediate insider selling.